BIG Research Programmes

Learn more about TRANSBIG

NeoBIG is a biomarkers and drug development research programme centred around neo-adjuvant studies. Learn more

Print

Large-scale cooperation is crucial to make significant  advances in breast cancer research, reduce the wasteful duplication of effort, and optimally serve those affected by the disease.

The Breast International Group (BIG), a non-profit organisation for academic breast cancer research groups, facilitates breast cancer research internationally by stimulating cooperation between its members and other academic networks, and collaborating with, but working independently from, the pharmaceutical industry.

 

News

18/10/2011 - EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study

The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemotherapy Trial) study. More than 6,600 patients in 111 institutions across nine countries were enrolled from February 2007 to July 2011 in this trial.


© 2012 Breast International Group (BIG)-aisbl